Abiopharma

News list

Krutz John Robert 🟢 acquired 1.2K shares (2 derivative) of Calumet, Inc. /DE (CLMT) Transaction Date: Mar 31, 2026 | Filing ID: 000002

Full text

News bot April 2, 2026, 8:13 p.m.
🔍 Krutz John Robert (Executive)

Company: Calumet, Inc. /DE (CLMT)

Report Date: 2026-03-31
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 1,241
Detailed Transactions and Holdings:
- Acquired 931 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 931.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
- Acquired 310 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 310.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
Footnotes:
- F1: Each Restricted Stock Unit is the economic equivalent of one share of Calumet, Inc. common stock, par value $0.01 per share.
- F2: Each Restricted Stock Unit will become settled upon the earlier of the date specified by the reporting person or the reporting person's termination date. Restricted Stock Units are 100% vested.
- F3: Each Restricted Stock Unit will be settled upon the earlier of the date specified by the reporting person or the reporting person's termination date pursuant to the Deferred Compensation Plan. 25% of the Restricted Stock Units vest on July 1 of each year beginning on July 1, 2027.